## Djuna L Cahen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/839028/publications.pdf

Version: 2024-02-01

28 papers 1,202 citations

623734 14 h-index 25 g-index

28 all docs 28 does citations

28 times ranked

1605 citing authors

#	Article	IF	Citations
1	Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut, 2022, 71, 1152-1160.	12.1	84
2	Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Gastroenterology, 2022, 162, 772-785.e4.	1.3	60
3	International external validation of a stratification tool to identify branchâ€duct intraductal papillary mucinous neoplasms at lowest risk of progression. United European Gastroenterology Journal, 2022, 10, 169-178.	3.8	6
4	Size and Concentration of Extracellular Vesicles in Pancreatic Juice From Patients With Pancreatic Ductal Adenocarcinoma. Clinical and Translational Gastroenterology, 2022, 13, e00465.	2.5	3
5	Protein biomarkers in pancreatic juice and serum for identification of pancreatic cancer. Gastrointestinal Endoscopy, 2022, 96, 801-813.e2.	1.0	8
6	Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic <i>CDKN2A</i> variants. Journal of Medical Genetics, 2021, 58, 264-269.	3.2	13
7	Identifying key factors for the effectiveness of pancreatic cancer screening: A modelâ€based analysis. International Journal of Cancer, 2021, 149, 337-346.	5.1	8
8	Endoscopic radiofrequency ablation to prolong survival for unresectable extrahepatic biliary cancer. Gastrointestinal Endoscopy, 2021, 94, 101-102.	1.0	0
9	Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes. Diabetes and Metabolism, 2021, 47, 101223.	2.9	25
10	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 2020, 69, 7-17.	12.1	357
11	Fully covered self-expandable metal stents for benign biliary strictures: an effective alternative. Endoscopy, 2020, 52, 334-335.	1.8	O
12	Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. Familial Cancer, 2020, 19, 247-258.	1.9	7
13	Optimization of Pancreatic Juice Collection: A First Step Toward Biomarker Discovery and Early Detection of Pancreatic Cancer. American Journal of Gastroenterology, 2020, 115, 2103-2108.	0.4	14
14	Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression. Alimentary Pharmacology and Therapeutics, 2019, 50, 789-799.	3.7	21
15	Editorial: when, who and howâ€"the everâ€evolving management of pancreatic cystic lesions. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 829-830.	3.7	0
16	Pancreatic cyst surveillance imposes low psychological burden. Pancreatology, 2019, 19, 1061-1066.	1.1	8
17	Evolution of features of chronic pancreatitis during endoscopic ultrasound-based surveillance of individuals at high risk for pancreatic cancer. Endoscopy International Open, 2018, 06, E541-E548.	1.8	8
18	Predictors of Progression Among Low-Risk Intraductal Papillary Mucinous Neoplasms in a Multicenter Surveillance Cohort. Pancreas, 2018, 47, 471-476.	1.1	22

#	Article	IF	CITATIONS
19	A biodegradable non-covered self-expandable stent to treatÂpancreatic duct strictures in chronic pancreatitis: aÂproofÂof principle. Gastrointestinal Endoscopy, 2018, 87, 486-491.	1.0	32
20	Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial. Diabetes Care, 2017, 40, 301-308.	8.6	15
21	Surveillance for neoplasia in the pancreas. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 971-986.	2.4	21
22	Follow-up of asymptomatic pancreatic cysts in clinical practice: AÂvignette questionnaire. Pancreatology, 2016, 16, 416-422.	1.1	8
23	Biliary effects of liraglutide and sitagliptin, a 12â€week randomized placeboâ€controlled trial in type 2 diabetes patients. Diabetes, Obesity and Metabolism, 2016, 18, 1217-1225.	4.4	39
24	Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia, 2016, 59, 2588-2593.	6.3	105
25	Testing for Anti-PBP Antibody Is Not Useful in Diagnosing Autoimmune Pancreatitis. American Journal of Gastroenterology, 2016, 111, 1650-1654.	0.4	11
26	GLP-1 based therapies: clinical implications for gastroenterologists. Gut, 2016, 65, 702-711.	12.1	34
27	Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open, 2015, 5, e009579.	1.9	30
28	Long-term Outcomes of Endoscopic vs Surgical Drainage of the Pancreatic Duct in Patients With Chronic Pancreatitis. Gastroenterology, 2011, 141, 1690-1695.	1.3	263